八木, 秀介 Shikoku Central Hospital|Tokushima University KAKEN研究者をさがす
Nishiyama, Seiichi Shikoku Central Hospital
Abe, Toshio Shikoku Central Hospital
佐田, 政隆 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
A Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by thrombembolic events including thromboembolism (VTE) in association with the presence of antiphospholipid antibodies. The standard treatment of VTE historically consists of anticoagulation therapy with warfarin, a vitamin K antagonist. Recently, direct oral anticoagulants, including rivaroxaban have become available for the treatment of VTE. However, the choice of anticoagulant, and the duration of anticoagulation in patients with APS has not been determined yet due to lack of evidence. Here, we report a case of recurrent venous thrombosis after discontinuation of rivaroxaban therapy and avoiding sedentary life style in a patient with APS. We suggest that indefinite anticoagulation therapy might be needed even in low risk APS cases.
BMJ Case Reports
BMJ Publishing Group
This article has been accepted for publication in BMJ Case Reports, 2019 following peer review, and the Version of Record can be accessed online at https://doi.org/10.1136/bcr-2018-227663.
bcr_12_1_e227663.pdf 1.71 MB